Published in J Appl Physiol (1985) on August 13, 2009
Nestin expression in end-stage disease in dystrophin-deficient heart: implications for regeneration from endogenous cardiac stem cells. Stem Cells Transl Med (2013) 0.89
Injection of vessel-derived stem cells prevents dilated cardiomyopathy and promotes angiogenesis and endogenous cardiac stem cell proliferation in mdx/utrn-/- but not aged mdx mouse models for duchenne muscular dystrophy. Stem Cells Transl Med (2012) 0.86
Nestin expression in mesenchymal stromal cells: regulation by hypoxia and osteogenesis. BMC Vet Res (2014) 0.81
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42
Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med (2011) 11.99
Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med (2014) 11.77
Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med (2004) 9.67
Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation (2005) 8.76
Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med (2010) 8.28
Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med (2012) 8.28
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med (2005) 6.86
Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA (2003) 6.39
A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med (2009) 5.81
An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm (2009) 4.99
Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research. Med Care (2005) 4.30
The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. J Thorac Cardiovasc Surg (2007) 3.45
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation (2002) 3.34
Can cardiologists distinguish innocent from pathologic murmurs in neonates? J Pediatr (2008) 2.74
Brugada syndrome: report of the second consensus conference. Heart Rhythm (2005) 2.48
Natural history of Brugada syndrome: the prognostic value of programmed electrical stimulation of the heart. J Cardiovasc Electrophysiol (2003) 2.44
Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol (2007) 2.40
Short QT syndrome and atrial fibrillation caused by mutation in KCNH2. J Cardiovasc Electrophysiol (2005) 2.39
De novo KCNQ1 mutation responsible for atrial fibrillation and short QT syndrome in utero. Cardiovasc Res (2005) 2.27
Current electrocardiographic criteria for diagnosis of Brugada pattern: a consensus report. J Electrocardiol (2012) 2.26
Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. Hypertension (2007) 2.22
Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet (2002) 2.16
Effect of opening a new catheterization laboratory on 30-day and 2-year survival rates in myocardial infarction patients. Rev Esp Cardiol (2011) 2.14
Familial pseudo-Wolff-Parkinson-White syndrome. J Cardiovasc Electrophysiol (2006) 2.11
Insights from the STICH trial: change in left ventricular size after coronary artery bypass grafting with and without surgical ventricular reconstruction. J Thorac Cardiovasc Surg (2012) 2.10
Navigating the crossroads of coronary artery disease and heart failure. Circulation (2006) 2.06
Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. Circulation (2010) 2.00
Should patients with an asymptomatic Brugada electrocardiogram undergo pharmacological and electrophysiological testing? Circulation (2005) 1.94
Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation (2003) 1.92
Electrocardiographic changes predicting sudden death in propofol-related infusion syndrome. Heart Rhythm (2006) 1.91
Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. Circulation (2002) 1.91
Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction. J Am Coll Cardiol (2002) 1.87
Short QT syndrome: pharmacological treatment. J Am Coll Cardiol (2004) 1.87
The nomenclature, definition and classification of cardiac structures in the setting of heterotaxy. Cardiol Young (2007) 1.83
Cryptic 5' splice site activation in SCN5A associated with Brugada syndrome. J Mol Cell Cardiol (2004) 1.81
Induced Brugada-type electrocardiogram, a sign for imminent malignant arrhythmias. Circulation (2008) 1.81
Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol (2005) 1.74
Electrophysiologic testing predicts events in Brugada syndrome patients. Heart Rhythm (2011) 1.70
Phenotypic characterization of a large European family with Brugada syndrome displaying a sudden unexpected death syndrome mutation in SCN5A:. J Cardiovasc Electrophysiol (2004) 1.69
Gender differences in clinical manifestations of Brugada syndrome. J Am Coll Cardiol (2008) 1.67
Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. J Am Coll Cardiol (2013) 1.65
Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA (2003) 1.64
Meta-analysis of the effects of endothelin receptor blockade on survival in experimental heart failure. J Card Fail (2003) 1.64
Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences. Circulation (2008) 1.61
State of the art in forensic investigation of sudden cardiac death. Am J Forensic Med Pathol (2011) 1.61
Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation (2004) 1.59
Ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarction. Circulation (2002) 1.57
Genetic and biophysical basis for bupivacaine-induced ST segment elevation and VT/VF. Anesthesia unmasked Brugada syndrome. Heart Rhythm (2006) 1.56
Trends in heart failure outcomes and pharmacotherapy: 1992 to 2000. Am J Med (2004) 1.55
Brugada syndrome: 1992-2002: a historical perspective. J Am Coll Cardiol (2003) 1.54
Differences in 12-lead electrocardiogram between symptomatic and asymptomatic Brugada syndrome patients. J Cardiovasc Electrophysiol (2007) 1.52
Phenotypical manifestations of mutations in the genes encoding subunits of the cardiac sodium channel. Circ Res (2011) 1.51
The cloning, genomic organization and tissue expression profile of the human DLG5 gene. BMC Genomics (2002) 1.50
Fever and Brugada syndrome. Pacing Clin Electrophysiol (2002) 1.48
Shocking truths about implantable cardioverter defibrillator monitoring zones. Pacing Clin Electrophysiol (2007) 1.48
Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement. Europace (2013) 1.47
Angina pectoris prior to myocardial infarction protects against subsequent left ventricular remodeling. J Am Coll Cardiol (2004) 1.47
Recommendations for the use of genetic testing in the clinical evaluation of inherited cardiac arrhythmias associated with sudden cardiac death: Canadian Cardiovascular Society/Canadian Heart Rhythm Society joint position paper. Can J Cardiol (2011) 1.47
Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network. J Card Fail (2012) 1.43
KCNE2 modulation of Kv4.3 current and its potential role in fatal rhythm disorders. Heart Rhythm (2009) 1.43
Systemic arterial pressure at maturity in rats following chronic hypoxia in early life. Am J Hypertens (2010) 1.43
Rebuttal to EP testing does not predict cardiac events in patients with Brugada syndrome. Heart Rhythm (2011) 1.39
Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology (2006) 1.34
Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Arch Intern Med (2004) 1.33
Influence of baseline left ventricular function on the clinical outcome of surgical ventricular reconstruction in patients with ischaemic cardiomyopathy. Eur Heart J (2012) 1.33
Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. J Am Coll Cardiol (2003) 1.32
Changes in connexin expression and the atrial fibrillation substrate in congestive heart failure. Circ Res (2009) 1.29
A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. Am J Hum Genet (2005) 1.29
Genetic fate mapping identifies second heart field progenitor cells as a source of adipocytes in arrhythmogenic right ventricular cardiomyopathy. Circ Res (2009) 1.28
Cellular senescence in endothelial cells from atherosclerotic patients is accelerated by oxidative stress associated with cardiovascular risk factors. Mech Ageing Dev (2007) 1.28
Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. J Am Soc Nephrol (2006) 1.26
Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Am Heart J (2008) 1.24
Impact of care at a multidisciplinary congestive heart failure clinic: a randomized trial. CMAJ (2005) 1.23
Atrial cardiomyocyte tachycardia alters cardiac fibroblast function: a novel consideration in atrial remodeling. Cardiovasc Res (2007) 1.22
Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J (2011) 1.20
Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren. Eur J Heart Fail (2011) 1.18
The MTHFD1 p.Arg653Gln variant alters enzyme function and increases risk for congenital heart defects. Hum Mutat (2009) 1.16
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J (2006) 1.15
Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study. Circulation (2004) 1.15
Value of electrocardiographic parameters and ajmaline test in the diagnosis of Brugada syndrome caused by SCN5A mutations. Circulation (2004) 1.14
Characterization of a hyperpolarization-activated time-dependent potassium current in canine cardiomyocytes from pulmonary vein myocardial sleeves and left atrium. J Physiol (2004) 1.14
Inferior and lateral electrocardiographic repolarization abnormalities in Brugada syndrome. Circ Arrhythm Electrophysiol (2009) 1.11
Beneficial effects of long-term use of the antioxidant probucol in heart failure in the rat. Circulation (2002) 1.11
Brugada syndrome unmasked by pneumonia. Tex Heart Inst J (2006) 1.10
Genetic modulation of brugada syndrome by a common polymorphism. J Cardiovasc Electrophysiol (2009) 1.09
Compound heterozygous mutations P336L and I1660V in the human cardiac sodium channel associated with the Brugada syndrome. Circulation (2006) 1.08
Brugada syndrome: from cell to bedside. Curr Probl Cardiol (2005) 1.08
Female rats fed a high-fat diet were associated with vascular dysfunction and cardiac fibrosis in the absence of overt obesity and hyperlipidemia: therapeutic potential of resveratrol. J Pharmacol Exp Ther (2008) 1.06
Essential role of protein kinase C delta in platelet signaling, alpha IIb beta 3 activation, and thromboxane A2 release. J Biol Chem (2006) 1.05